Search Results
Your search for 3 matches 15113 pages
Showing 2801 - 2850Neoadjuvant Nivolumab Plus Ipilimumab in Localized dMMR/MSI-H Gastric Cancer
As reported in the Journal of Clinical Oncology by Thierry André, MD, and colleagues, the French (GERCOR) phase II NEONIPIGA trial has shown a high pathologic complete response rate with nivolumab/ipilimumab neoadjuvant therapy in patients with localized deficient mismatch repair...
Elotuzumab Plus Pomalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: ELOQUENT-3 Overall Survival Analysis
As reported in the Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, and colleagues, the final overall survival analysis of the phase II ELOQUENT-3 trial showed significant benefit with the addition of elotuzumab to pomalidomide and dexamethasone (EPd) vs pomalidomide and dexamethasone...
Adding CT to X-Ray for Follow-up of Completely Resected NSCLC
In a French phase III trial (IFCT-0302) reported in The Lancet Oncology, Westeel et al found that a strategy including computed tomography (CT) and x-ray vs x-ray alone did not improve overall survival when used in the follow-up of patients with completely resected non–small cell lung cancer...
Harry P. Erba, MD, PhD, on AML: New Data on Quizartinib Plus Standard Chemotherapy
Harry P. Erba, MD, PhD, of Duke Cancer Institute, discusses potentially practice-changing phase III results from the QuANTUM-First trial, which showed that adding quizartinib to standard chemotherapy and up to 3 years of continuation therapy led to improvement in overall survival for adults aged 18 ...
Study Examines Effects of Advance Care Planning for Adolescents With Cancer
In a recently published study by Needle et al in JAMA Network Open, University of Minnesota researchers and colleagues say adolescents with cancer deserve a voice in medical decisions made for and about them. “Adolescents with cancer should be given the opportunity to participate in their own...
Cancer-Related Fatigue Linked to Balance Problems After Chemotherapy for Breast Cancer
For many patients who have received chemotherapy for breast cancer, cancer-related fatigue is a persistent side effect—and one that contributes to ongoing balance problems, suggests a recent paper published by Weschler et al in Rehabilitation Oncology. The new research by Stephen Wechsler, PT, DPT, ...
Rituximab, Lenalidomide, and Ibrutinib With Sequential Addition of Chemotherapy in Newly Diagnosed DLBCL: Smart Start Trial
In a single-institution phase II trial (Smart Start) reported in the Journal of Clinical Oncology, Jason Westin, MD, MS, and colleagues found that initiating treatment with rituximab, lenalidomide, and ibrutinib (RLI) followed by the sequential addition of chemotherapy resulted in high response...
Durvalumab/Tremelimumab for Previously Treated Patients With Advanced Soft-Tissue and Bone Sarcomas
In a single-center phase II trial reported in The Lancet Oncology, Somaiah et al found that the combination of durvalumab and tremelimumab showed activity in a group of previously treated patients with advanced or metastatic soft-tissue and bone sarcomas of various subtypes. Study Details In the...
New Guideline Updates Address Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations
Two ASCO guideline updates provide new evidence-based recommendations for the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations.1,2 Among several other updates, these new guidelines add the ALK and ROS1 inhibitor lorlatinib and the PD-L1 immune...
Lisocabtagene Maraleucel in Second-Line Treatment of Large B-Cell Lymphoma
On June 24, 2022, lisocabtagene maraleucel was approved for adults with large B-cell lymphoma (LBCL) who have (1) refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or (2) refractory disease to first-line chemoimmunotherapy or relapse...
Rucaparib Maintenance After Platinum-Based Chemotherapy for Metastatic Urothelial Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Simon J. Crabb, BSc, MBBS, MRCP, PhD, and colleagues found that maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib vs placebo was associated with prolonged progression-free survival in patients with...
Racial Trends in Advanced Cervical Cancer in the United States
The steepest annual rise in new cases of advanced cervical cancer in the United States from 2001 to 2018 was among White patients, who were significantly less likely to receive the preventive human papillomavirus (HPV) vaccine or to be screened for the disease, according to research published by...
APHINITY Trial in Patients With HER2-Positive Early Breast Cancer: Update at 8 Years
Updated results from the adjuvant APHINITY trial in HER2-positive early breast cancer, now with a median follow-up of 8.4 years, confirmed the benefit of adding pertuzumab to trastuzumab plus chemotherapy in preventing invasive disease recurrences, but as yet no statistically significant overall...
Crizotinib in Adult and Pediatric ALK-Positive Inflammatory Myofibroblastic Tumors
On July 14, 2022, crizotinib was approved for adult and pediatric patients aged ≥ 1 year with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter studies ADVL0912 (ClinicalTrials.gov...
Sequencing Therapies May Improve Overall Survival in Metastatic Pancreatic Cancer
In the first-line treatment of metastatic pancreatic cancer, the sequencing of nab-paclitaxel plus gemcitabine with FOLFOX (fluorouracil, leucovorin, oxaliplatin) resulted in a significant improvement in overall survival at 12 months and in all other efficacy endpoints as compared with the standard ...
Effect of Physical Activity on Disease-Free Survival in Patients Receiving Adjuvant Therapy for Stage III Colon Cancer
As reported in the Journal of Clinical Oncology by Brown et al, a prospective cohort study nested within the phase III CALGB/SWOG 80702/Alliance trial showed that greater volumes of physical activity in patients receiving adjuvant therapy for stage III colon cancer were associated with significant...
Snapshots of Studies of Interest Presented at ASCO 2022
The 2022 ASCO Annual Meeting was filled with important science, engaging data, and several practice-changing abstracts, many of which have been covered in detail on other pages or in earlier issues of The ASCO Post. There were numerous high-impact studies and attendees, whether present at the...
Impact of the Dobbs v Jackson Women’s Health Organization Ruling on Patients With Cancer
As a nonpartisan organization, the American Cancer Society has an overarching goal to improve the lives of patients with cancer and their families. We believe all individuals should have an equitable opportunity to prevent, find, detect, and survive cancer, irrespective of geography. The June 24...
Is Science Getting Closer to Preventing Multiple Myeloma?
About 3 years ago, researchers from Dana-Farber Cancer Institute launched PROMISE (Predicting Progression of Developing Myeloma in a High-Risk Screen Population; ClinicalTrials.gov identifier NCT03689595), a large, ambitious screening study to identify individuals at high risk of developing...
Epcoritamab Under Study in Difficult-to-Treat Large B-Cell Lymphoma
Subcutaneous epcoritamab, a bispecific antibody, has demonstrated deep and durable responses in a large expansion cohort of patients with relapsed or refractory large B-cell lymphoma (LBCL), according to late-breaking data presented during the European Hematology Association (EHA) 2022 Congress in...
Real-World Evidence Confirms Survival Benefit of Durvalumab in Locally Advanced Non–Small Cell Lung Cancer
In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and...
Atezolizumab Plus Vemurafenib/Cobimetinib for Patients With BRAF V600–Mutated Melanoma and CNS Metastases
In the phase II TRICOTEL study reported in The Lancet Oncology, Reinhard Dummer, MD, and colleagues found that the combination of atezolizumab plus vemurafenib and cobimetinib produced durable intracranial responses in patients with BRAF V600–mutated melanoma and central nervous system (CNS)...
Study Tests Strategy for Reducing Colorectal Cancer Risk Among Patients With Familial Adenomatous Polyposis
Researchers from the Mayo Clinic Comprehensive Cancer Center and the Mayo Clinic Center for Individualized Medicine are studying the rare genetic condition called familial adenomatous polyposis, looking for potential ways to prevent colorectal cancer in the general population at an earlier, more...
Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, de Vries et al developed risk models for predicting the development of coronary heart disease and heart failure in patients treated for Hodgkin lymphoma. Study Details The prediction models were developed in a Dutch cohort of 1,433 5-year...
Is Advance Care Planning of Any Value?
An article in The New York Times earlier this year crystallized the dilemma facing health-care providers when they are presented with a patient in a life-threatening situation: Should they rely on advance care directives written years prior to the current medical situation to accurately determine...
T-DXd Shows High Intracranial Response Rate in Patients With Active Brain Metastases From HER2-Positive Breast Cancer
In the investigator-initiated, prospective, open-label, single-arm phase II TUXEDO-1 study conducted among patients with newly diagnosed or progressive brain metastases from HER2-positive breast cancer, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) yielded responses according...
Low-Dose Decitabine and Azacitidine in Lower-Risk MDS
As reported in NEJM Evidence by Sasaki et al, extended follow-up of a phase II trial showed good outcomes with low doses of the hypomethylating agents decitabine and azacitidine in previously untreated patients with lower-risk myelodysplastic syndromes (MDS). Study Details The study included 113...
RATIONALE-306: Survival Benefit Attained With Tislelizumab in Advanced Esophageal Cancer
In patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of the checkpoint inhibitor tislelizumab to first-line chemotherapy significantly improved overall survival vs chemotherapy alone, according to an interim analysis of the global phase III RATIONALE-306 trial....
Pralsetinib Achieves Tissue-Agnostic Benefits for Patients With RET Fusion–Positive Cancers
The highly selective RET inhibitor pralsetinib was well tolerated and demonstrated robust, durable responses in patients with RET fusion–positive cancers regardless of tumor type, according to results from the international phase I/II ARROW trial. Results from the trial were published in Nature...
WBI With Boost After Breast-Conserving Surgery in Non–Low-Risk DCIS
As reported in The Lancet by Chua et al, the phase III BIG 3-07/TROG 07.01 trial has shown reduced risk of local recurrence with vs without tumor bed boost after conventional or hypofractionated whole-breast irradiation (WBI) in women receiving breast-conserving surgery for non–low-risk ductal...
A Surgical Oncologist From Afghanistan Discusses the Challenges of Delivering Cancer Care in a War-Torn Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ahmad Bashir Barekzai, MD, FACS, Consultant Surgical Oncologist at Ali Abad Teaching Hospital, an affiliated hospital to Kabul University of Medical Science, Kabul,...
Sugemalimab Found to Be a Safe and Effective Consolidation Therapy for Patients With Unresectable Stage III NSCLC
The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to...
Breast Induration Risk With Partial- vs Whole-Breast Irradiation After Breast-Conserving Surgery for Node-Negative Early Disease
As reported in the Journal of Clinical Oncology by Offersen et al, the phase III Danish Breast Cancer Group Partial Breast Irradiation Trial showed that partial-breast irradiation was noninferior to whole-breast irradiation in terms of the risk for breast induration in women aged ≥ 60 years...
Locoregional Recurrence With Predefined Risk-Based De-escalation of Radiotherapy After Primary Chemotherapy in cT1–2N1 Breast Cancer
As reported in The Lancet Oncology by de Wild et al, 5-year follow-up from a Dutch prospective registry study (RAPCHEM, BOOG 2010-03) showed low rates of locoregional recurrence with de-escalation of adjuvant radiotherapy according to predefined risk levels in women receiving primary chemotherapy...
INTRIGUE Trial: Second-Line Ripretinib vs Sunitinib in Advanced GIST
As reported in the Journal of Clinical Oncology by Bauer et al, the phase III INTRIGUE trial showed no significant progression-free survival benefit with second-line ripretinib vs sunitinib in imatinib-pretreated patients with gastrointestinal stromal tumor (GIST), including among patients with KIT ...
Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study
Researchers from Japan recently reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1–positive unresectable locally advanced non–small cell lung cancer (NSCLC) without chemotherapy met its primary endpoint with...
Models to Assess Impact of Centralization of Specialist Cancer Services in England
In a study reported in The Lancet Oncology, Aggarwal et al identified the impact of several models of centralization of specialist cancer services in England, using rectal cancer surgery as an example. As stated by the investigators, “Centralization of specialist cancer services is occurring in...
Time to Initiation of Adjuvant Endocrine Therapy and Likelihood of Adherence in Medicaid-Insured Women With Breast Cancer
In a population-based retrospective cohort study reported in JAMA Network Open, Sood et al found that longer time to adjuvant endocrine therapy initiation in Medicaid-insured women with breast cancer was associated with a reduced likelihood of short- and long-term adherence to treatment. As stated...
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for HER2-Mutant NSCLC
On August 11, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for adult patients with unresectable or metastatic non–small cell lung cancer (NSCLC) whose tumors have activating HER2 mutations, as detected by an...
FDA Approves Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutations
On August 10, 2022, the U.S. Food and Drug Administration (FDA) granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an ...
Research Suggests Air Pollution Be Included as Risk Factor for Nonsmoking Patients With Lung Cancer
Researchers from Vancouver, British Columbia examined the effect of duration of past exposure to air pollution with lung cancer diagnosis in new research presented by Myers et al at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2022 (Abstract...
Evaluating Strategies for Treating Pediatric Metastatic Rhabdomyosarcoma
In a report in the Journal of Clinical Oncology, Schoot et al provided findings from the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 and pooled findings of MTS 2008 with those of the concurrent BERNIE study, both of which evaluated strategies for the treatment of pediatric...
ASCO-ACCC Recommendations to Reduce Barriers to Clinical Trial Enrollment
Here is a summary of the strategies developed by ASCO and the Association of Community Cancer Centers (ACCC) to increase participation by minority patients in cancer clinical trials and ensure greater equity, diversity, and inclusion in research studies. For a detailed list of the recommendations,...
How ASCO and ACCC Aim to Increase Diversity in Clinical Trials and Close the Equity Gap in Cancer Care
Research shows that although 15% of Black individuals and 13% of Hispanic individuals have cancer in the United States, only between 4% and 6% of clinical trial participants are Black and between 3% and 6% are Hispanic.1-3 To improve these statistics, in 2020, ASCO and the Association of Community...
Initiatives by Professional Oncology Organizations Focus on Improving Equitable Cancer Care
At the 2022 Summit on Cancer Health Disparities in Seattle, leaders from five of the leading professional societies in cancer discussed their respective organizations’ current initiatives toward improving cancer health disparities.1 Representatives from ASCO, the American Society for Clinical...
Long-Term Regional Disease Control With Sentinel Lymph Node Biopsy in Patients With Melanoma
In an analysis of the Multicenter Selective Lymphadenectomy Trial II reported in JAMA Surgery, Crystal et al found that patients with melanoma with sentinel lymph node (SLN) metastasis who were randomly assigned to observation vs completion lymph node dissection (CLND) following SLN biopsy...
ASCO Releases First Comprehensive Evidence-Based Guidelines for Metastatic Clear Cell Renal Cell Carcinoma
ASCO has released the first comprehensive set of guidelines for the management of metastatic clear cell renal cell carcinoma (RCC).1 The guidelines are subdivided into six main sections: diagnosis, the role of cytoreductive nephrectomy, first-line systemic treatment, second- or later-line systemic...
ASCO Endorses New ASTRO Guideline on the Use of Radiation Treatment of Metastatic Brain Cancer
ASCO has endorsed the recommendations put forth in a new guideline, developed by the American Society for Radiation Oncology (ASTRO), on the use of radiation therapy for the management of brain metastases.1,2 Although ASTRO—in conjunction with ASCO and the Society for Neuro-Oncology (SNO)—recently...
Addition of Transarterial Chemoembolization to Lenvatinib in First-Line Treatment of Advanced Hepatocellular Carcinoma
An interim analysis of the Chinese phase III LAUNCH trial was reported in the Journal of Clinical Oncology by Peng et al. The researchers found that the addition of transarterial chemoembolization to lenvatinib improved overall survival in patients with advanced hepatocellular carcinoma who were...
Cancer Knows No Borders
This is a critical time for cancer research and cancer care across the world, and the cancer community has clearly highlighted the need for greater and more equitable international collaboration. Addressing the global cancer challenge is a significant undertaking, and it has become more urgent as ...
